

APPLIED RESEARCH AND DEVELOPMENT EXPENDITURES^{1/}

In 1965, more than half of the industry's applied research and development funds were directed toward the creation of drugs to be effective in three classes: (1) central nervous system and sense organ disorders; (2) parasitic and infective diseases; and (3) neoplasms, endocrine system and metabolic diseases. Table 24 is a breakdown by therapeutic purpose of the reporting firms' applied research and development expenditures in the United States.

Table 24

DISTRIBUTION OF APPLIED RESEARCH AND
DEVELOPMENT EXPENDITURES BY
THERAPEUTIC PURPOSE, 1965

	Company Financed U. S. R&D Funds		
	Number of Firms	Expen- ditures (millions)	Per- centage
<u>Research for the Discovery and Development</u>			
<u>For Human Use of:</u>			
Drugs for central nervous system and sense organs	(37)	\$ 37.1	19.0%
Drugs affecting parasitic and infective diseases . . .	(21)	33.9	17.4
Drugs for neoplasms, endocrine system and metabolic diseases	(27)	32.8	16.8
Drugs acting on cardiovascular system	(36)	18.8	9.7
Drugs acting on digestive or genito-urinary systems .	(32)	15.1	7.8
Biologicals	(13)	8.4	4.3
Drugs acting on respiratory system	(26)	5.5	2.8
Vitamins, nutrients and hematinics.	(17)	4.6	2.4
Diagnostic agents.	(20)	4.0	2.1
Drugs acting on skin.	(17)	3.4	1.7
Other pharmaceutical preparations	(25)	18.5	9.5
<u>Research for the Discovery and Development</u>			
<u>For Animal Use of:</u>			
Pharmaceutical preparations	(18)	9.9	5.1
Biologicals	(12)	2.7	1.4
TOTAL	(42)	\$194.7	100.0%

^{1/} Based on responses from 42 member firms.